arXiv:2503.03503q-bio.BMcs.AI2025-03被引 22

用两个AI专家协作优化药物分子,成功率超八成。

Collaborative Expert LLMs Guided Multi-Objective Molecular Optimization

  • 两个AI分工:一个学数据生成分子,一个查文献找知识。
  • 六项任务中成功率达82.3%,远超现有方法的27.5%。
  • 适合药物研发人员快速优化分子属性,如选择性与生物利用度。

分子优化是药物研发中关键但复杂且耗时的环节,传统方法依赖试错,多目标优化效率低。现有AI方法在处理多目标任务上表现有限。为此,我们提出MultiMol,一种由两个代理构成的协作式大语言模型系统:数据驱动型工作代理通过微调学习多目标分子生成,文献引导型研究代理则检索相关文献以获取先验知识,辅助识别最优候选分子。在六个多目标优化任务上的评估显示,MultiMol成功率高达82.30%,显著优于当前最强方法的27.50%。进一步验证中,我们成功将促效剂Xanthine Amine Congener(XAC)的选择性从同时结合A1R和A2AR调整为偏向A1R;并提升了艾滋病毒蛋白酶抑制剂Saquinavir的生物利用度。结果表明,MultiMol可有效加速药物研发进程,具有广阔应用前景。

原文摘要 · Abstract (English)

Molecular optimization is a crucial yet complex and time-intensive process that often acts as a bottleneck for drug development. Traditional methods rely heavily on trial and error, making multi-objective optimization both time-consuming and resource-intensive. Current AI-based methods have shown limited success in handling multi-objective optimization tasks, hampering their practical utilization. To address this challenge, we present MultiMol, a collaborative large language model (LLM) system designed to guide multi-objective molecular optimization. MultiMol comprises two agents, including a data-driven worker agent and a literature-guided research agent. The data-driven worker agent is a large language model being fine-tuned to learn how to generate optimized molecules considering multiple objectives, while the literature-guided research agent is responsible for searching task-related literature to find useful prior knowledge that facilitates identifying the most promising optimized candidates. In evaluations across six multi-objective optimization tasks, MultiMol significantly outperforms existing methods, achieving a 82.30% success rate, in sharp contrast to the 27.50% success rate of current strongest methods. To further validate its practical impact, we tested MultiMol on two real-world challenges. First, we enhanced the selectivity of Xanthine Amine Congener (XAC), a promiscuous ligand that binds both A1R and A2AR, successfully biasing it towards A1R. Second, we improved the bioavailability of Saquinavir, an HIV-1 protease inhibitor with known bioavailability limitations. Overall, these results indicate that MultiMol represents a highly promising approach for multi-objective molecular optimization, holding great potential to accelerate the drug development process and contribute to the advancement of pharmaceutical research.

分子优化AI制药多目标优化LLM应用

Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品;中文卡片由大模型生成,请以原文为准。